Patients were tested after being unmedicated for a minimum of 7 days (6 weeks for two patients receiving fluoxetine), but most patients were drug-free for considerably longer or had not previously been treated with an antidepressant. Patients then received one of six treatments listed in Table 1, all of which included a SRI. A total of 16 patients received an SSRI alone, 15 received an SSRI plus an NDRI, and 10 received an SNRI. After 8–12 weeks of treatment, clinical response was assessed using with the Clinical Global Impression Improvement scale (CGI-I; 38) by a rater who was blind to the EEG data. Patients who had a CGI-I rating of “much improved” or “very much improved” were considered to be responders (n = 28) and all other patients were considered as nonresponders (n = 13). The final dosage levels for each antidepressant were comparable in responders and nonresponders (Table 1), who also did not differ from each other or from healthy controls in gender, age, education or handedness (Table 2). There was no significant difference between responders and nonresponders in
